RIPK1 and metabolic dysfunction-associated steatohepatitis: Previous studies, including our own, have linked RIPK1’s kinase activity to the pathogenesis of metabolic diseases like NASH, indicating a metabolic regulatory role of RIPK1 kinase (Majdi et al., 2020; Tao et al., 2021; Yan et al., 2022).